ARCHIVES

Ibrutinib Produces 68% Overall Response Rate in Phase II Trial

This article is from The Cancer Letter archive.

Vol. 36 No. 1 | January 25, 2013

Download PDF Visit The Full Archive

Related Articles

Unscreened Women At High Risk of Breast Cancer

October 29, 2004

NIH Reauthorization Compromise Between House and Senate Gives NCI Three Year Authorization Period

October 18, 1985

Controversial Toxicology Protocol Is “Getting The Information We Need;” Additionally Revision Made

March 2, 1984

Shubik Group Finishes Criteria, Presents Final Draft To Rauscher

July 2, 1976

Cancer Survivorship: NCI, Komen, OWH Fund Research Grants

December 5, 1997

NCAB Members Skeptical On NCI Reorganization; King Has “Alterative;” Terry T Head Centers

January 27, 1978